New Targeting in the Reversal of Resistant Glioblastomas

ISBN-13: 9780128225271 / Angielski / Twarda / 2021

Ali Syed Arbab

Recenzje

"New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field." --Anticancer Research

Spis treści

1. Current status of recurrent glioblastoma therapies

2. Imaging of glioblastoma recurrence

3. Overarching therapeutic challenges and arachidonic acid metabolism as a novel target in glioblastoma

4. The intervention of IL-8-CXCR2 axis to reverse the resistance to GBM therapies

5. Targeting Glioma Stem Cell Metabolism to Enhance Therapy Responses and Minimize Resistance

6. Targeting Tumor Microenvironment Associated Cells to Reverse Therapy Resistance

7. Recent Progress in Immunotherapy for Glioblastoma

8. The Role of Convection Enhanced Deliver in the Treatment of GBM

9. TBA Sensitization of Resistant GBM to Radiation

O autorze

Ali Syed Arbab, MD PHD, is Leader of Tumor Angiogenesis Initiative and Director, Core Imaging Facilities for Small Animals, both at Augusta University. Dr. Arbab's laboratory is devoted to determining the mechanisms of therapy resistance by focusing on the involvement of bone marrow derived cells in modulating the tumor microenvironment and initiating tumor neovascularization in glioblastoma models. To understand the involvement of bone marrow cells in developing resistance to antiangiogenic therapies (AAT), his group has developed chimeric animal models where bone marrow of the recipient animal is replaced with GFP+ bone marrow. Dr. Arbab's group documented that tumor-recruited bone marrow cells are a predominantly heterogeneous myeloid cell population that can predict therapeutic response in cancer, and they are using several strategies to target bone marrow or tumor-promoting myeloid cells to potentiate the anti-tumor effect of FDA-approved drugs in preclinical models of glioblastoma.